Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study | Zendy

A. John Camm | Zendy; Alexander G.G. Turpie | Zendy; Susanne Hess | Zendy; Pierre Amarenco | Zendy; Marc Lambelet | Zendy; Sylvia Haas | Zendy; Martin van Eickels | Zendy; Paulus Kirchhof | Zendy

Open Access

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study

Author(s) -

A. John Camm,

Alexander G.G. Turpie,

Susanne Hess,

Pierre Amarenco,

Marc Lambelet,

Sylvia Haas,

Martin van Eickels,

Paulus Kirchhof

Publication year - 2017

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/eux127

Subject(s) - medicine , cardioversion , atrial fibrillation , catheter ablation , cardiology , rivaroxaban , incidence (geometry) , prospective cohort study , ablation , observational study , adverse effect , warfarin , physics , optics

In patients with atrial fibrillation, catheter ablation and cardioversion carry a risk of peri-procedural thromboembolic events; current guidelines recommend anticoagulation in these settings. This study aimed to report the baseline demographics and clinical characteristics of patients enrolled in the prospective, observational XANTUS study who underwent catheter ablation or cardioversion, and adverse outcomes with each of these procedures in patients treated with rivaroxaban.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research